Rimini Street (RMNI) 10-Q 2 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares shares in Thousands	6 Months Ended
	Jun. 30, 2023	Jul. 31, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-37397
Entity Registrant Name	Rimini Street, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4880301
Entity Address, Address Line One	1700 S. Pavilion Center Drive
Entity Address, Address Line Two	Suite 330
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89135
City Area Code	(702)
Local Phone Number	839-9671
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		89,087
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001635282
Current Fiscal Year End Date	--12-31
Common Stock, par value $0.0001 per share
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	RMNI
Security Exchange Name	NASDAQ

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 123,543	$ 109,008
Restricted cash	427	426
Accounts receivable, net of allowance of $737 and $723, respectively	85,065	116,093
Deferred contract costs, current	17,590	17,218
Short-term investments	17,130	20,115
Prepaid expenses and other	21,239	18,846
Total current assets	264,994	281,706
Long-term assets:
Property and equipment, net of accumulated depreciation and amortization of $16,670 and $15,441, respectively	7,134	6,113
Operating lease right-of-use assets	7,138	7,142
Deferred contract costs, noncurrent	22,516	23,508
Deposits and other	8,156	7,057
Deferred income taxes, net	60,919	65,515
Total assets	370,857	391,041
Current liabilities:
Current maturities of long-term debt	5,912	4,789
Accounts payable	4,632	8,040
Accrued compensation, benefits and commissions	33,694	37,459
Other accrued liabilities	21,669	32,676
Operating lease liabilities, current	4,219	4,223
Deferred revenue, current	259,102	265,840
Total current liabilities	329,228	353,027
Long-term liabilities:
Long-term debt, net of current maturities	67,113	70,003
Deferred revenue, noncurrent	26,222	34,081
Operating lease liabilities, noncurrent	8,532	9,094
Other long-term liabilities	1,823	2,006
Total liabilities	432,918	468,211
Commitments and contingencies (Note 8)
Stockholders’ deficit:
Preferred stock; $0.0001 par value. Authorized 99,820 (excluding 180 shares of Series A Preferred Stock) no other series has been designated	0	0
Common stock; $0.0001 par value. Authorized 1,000,000 shares; issued and outstanding 89,085 and 88,517 shares, respectively	9	9
Additional paid-in capital	161,391	156,401
Accumulated other comprehensive loss	(3,983)	(4,195)
Accumulated deficit	(218,362)	(228,269)
Treasury stock, at cost	(1,116)	(1,116)
Total stockholders' deficit	(62,061)	(77,170)
Total liabilities and stockholders' deficit	$ 370,857	$ 391,041

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 737	$ 723
Accumulated depreciation and amortization	$ 16,670	$ 15,441
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (shares)	99,820,000	99,820,000
Series A preferred stock, shares authorized (shares)	180,000	180,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (shares)	89,085,000	88,517,000
Common stock, shares outstanding (shares)	89,085,000	88,517,000

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenue	$ 106,421	$ 101,200	$ 211,933	$ 199,110
Cost of revenue	39,348	37,344	78,691	74,551
Gross profit	67,073	63,856	133,242	124,559
Operating expenses:
Sales and marketing	37,284	36,205	71,763	67,905
General and administrative	18,865	18,862	37,092	38,813
Reorganization costs	0	0	59	0
Litigation costs and related recoveries:
Professional fees and other costs of litigation	629	3,193	3,348	6,692
Insurance costs and recoveries, net	0	(92)	0	(481)
Litigation costs and related recoveries, net	629	3,101	3,348	6,211
Total operating expenses	56,778	58,168	112,262	112,929
Operating income	10,295	5,688	20,980	11,630
Non-operating income and (expenses):
Interest expense	(1,387)	(999)	(2,726)	(1,807)
Other income (expenses), net	280	(1,577)	809	(1,368)
Income before income taxes	9,188	3,112	19,063	8,455
Income taxes	(4,920)	(3,002)	(9,156)	(5,258)
Net income	4,268	110	9,907	3,197
Other comprehensive income
Foreign currency translation gain (loss)	(89)	(2,025)	50	(2,211)
Derivative instrument and other adjustments, net of tax	937	0	162	0
Comprehensive income (loss)	5,116	(1,915)	10,119	986
Net income attributable to common stockholders	$ 4,268	$ 110	$ 9,907	$ 3,197
Net income per share attributable to common stockholders:
Basic (in dollars per share)	$ 0.05	$ 0	$ 0.11	$ 0.04
Diluted (in dollars per share)	$ 0.05	$ 0	$ 0.11	$ 0.04
Weighted average number of shares of Common Stock outstanding:
Weighted average number of shares outstanding, basic (shares)	88,903	87,225	88,797	87,175
Weighted average number of shares outstanding, diluted (shares)	89,274	89,339	89,251	88,940

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Treasury Stock
Beginning balance (shares) at Dec. 31, 2021		87,107
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash (shares)		325
Restricted stock units vested (shares)		690
Issuance of Common Stock (shares)		60
Retired shares of Common Stock (shares)		(653)
Ending balance (shares) at Jun. 30, 2022		87,529
Stockholders' deficit, beginning of period at Dec. 31, 2021	$ (80,386)	$ 9	$ 149,234	$ (2,724)	$ (225,789)
Treasury Stock at Dec. 31, 2021						$ (1,116)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash		0	451
Restricted stock units vested		0	0
Retired shares of Common Stock		0	(3,748)
Stock based compensation expense			6,210
Other comprehensive loss				(2,211)
Net income	3,197				3,197
Treasury Stock at Jun. 30, 2022						(1,116)
Stockholders' deficit, end of period at Jun. 30, 2022	(76,487)	$ 9	152,147	(4,935)	(222,592)
Beginning balance (shares) at Mar. 31, 2022		87,011
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash (shares)		38
Restricted stock units vested (shares)		506
Issuance of Common Stock (shares)		60
Retired shares of Common Stock (shares)		(86)
Ending balance (shares) at Jun. 30, 2022		87,529
Stockholders' deficit, beginning of period at Mar. 31, 2022	(77,299)	$ 9	149,420	(2,910)	(222,702)
Treasury Stock at Mar. 31, 2022						(1,116)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash		0	76
Restricted stock units vested		0	0
Retired shares of Common Stock		0	(508)
Stock based compensation expense			3,159
Other comprehensive loss				(2,025)
Net income	110				110
Treasury Stock at Jun. 30, 2022						(1,116)
Stockholders' deficit, end of period at Jun. 30, 2022	$ (76,487)	$ 9	152,147	(4,935)	(222,592)
Beginning balance (shares) at Dec. 31, 2022		88,517
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash (shares)		57
Restricted stock units vested (shares)		684
Issuance of Common Stock (shares)	75	75
Retired shares of Common Stock (shares)		(248)
Ending balance (shares) at Jun. 30, 2023		89,085
Stockholders' deficit, beginning of period at Dec. 31, 2022	$ (77,170)	$ 9	156,401	(4,195)	(228,269)
Treasury Stock at Dec. 31, 2022	(1,116)					(1,116)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash		0	79
Restricted stock units vested		0	0
Retired shares of Common Stock		0	(1,014)
Stock based compensation expense			5,925
Other comprehensive loss				212
Net income	9,907				9,907
Treasury Stock at Jun. 30, 2023	(1,116)					(1,116)
Stockholders' deficit, end of period at Jun. 30, 2023	(62,061)	$ 9	161,391	(3,983)	(218,362)
Beginning balance (shares) at Mar. 31, 2023		88,883
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash (shares)		3
Restricted stock units vested (shares)		372
Issuance of Common Stock (shares)		75
Retired shares of Common Stock (shares)		(248)
Ending balance (shares) at Jun. 30, 2023		89,085
Stockholders' deficit, beginning of period at Mar. 31, 2023	(70,119)	$ 9	158,449	(4,831)	(222,630)
Treasury Stock at Mar. 31, 2023						(1,116)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options for cash		0	8
Restricted stock units vested		0	0
Retired shares of Common Stock		0	(1,014)
Stock based compensation expense			3,948
Other comprehensive loss				848
Net income	4,268				4,268
Treasury Stock at Jun. 30, 2023	(1,116)					$ (1,116)
Stockholders' deficit, end of period at Jun. 30, 2023	$ (62,061)	$ 9	$ 161,391	$ (3,983)	$ (218,362)

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 9,907	$ 3,197
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense	5,925	6,210
Depreciation and amortization	1,249	1,222
Accretion and amortization of debt discount and issuance costs	483	483
Deferred income taxes	4,415	511
Amortization and accretion related to operating right of use assets	2,237	2,781
Changes in operating assets and liabilities:
Accounts receivable	31,050	47,890
Prepaid expenses, deposits and other	(1,096)	(550)
Deferred contract costs	620	(3,201)
Accounts payable	(3,551)	38
Accrued compensation, benefits, commissions and other liabilities	(17,262)	(1,484)
Deferred revenue	(12,228)	3,676
Net cash provided by operating activities	21,749	60,773
CASH FLOWS USED IN INVESTING ACTIVITIES:
Capital expenditures	(2,095)	(1,722)
Payment for purchases of investments	(14,666)	0
Proceeds from sale of investments	15,621	0
Net cash used in investing activities	(1,140)	(1,722)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of professional fees related to March 2021 Common Stock offering	0	(27)
Principal payments on the Credit Facility	(2,250)	(7,250)
Payments to repurchase and retire Common Stock	(1,014)	(3,748)
Principal payments on capital leases	(163)	(157)
Proceeds from exercise of employee stock options	79	451
Net cash used in financing activities	(3,348)	(10,731)
Effect of foreign currency translation changes	(2,725)	(7,674)
Net change in cash, cash equivalents and restricted cash	14,536	40,646
Cash, cash equivalents and restricted cash at beginning of period	109,434	119,990
Cash, cash equivalents and restricted cash at end of period	123,970	160,636
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	2,256	1,277
Cash paid for income taxes	3,656	1,177
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Increase in payables for capital expenditures	$ 112	$ 61

NATURE OF BUSINESS AND BASIS OF

NATURE OF BUSINESS AND BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF BUSINESS AND BASIS OF PRESENTATION	NATURE OF BUSINESS AND BASIS OF PRESENTATION Nature of Business Rimini Street, Inc. (the “Company”) is a global provider of end-to-end enterprise software support, products and services. The Company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients’ enterprise application, database, and technology software platforms. Basis of Presentation and Consolidation The Unaudited Condensed Consolidated Financial Statements, which include the accounts of the Company and its wholly-owned subsidiaries, are prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”). All significant intercompany balances and transactions have been eliminated. The accompanying Unaudited Condensed Consolidated Financial Statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, certain information and footnote disclosures required by U.S. GAAP for complete financial statements have been condensed or omitted in accordance with such rules and regulations. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Unaudited Condensed Consolidated Financial Statements have been included. These Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company’s Audited Consolidated Financial Statements for the year ended December 31, 2022, included in the Company’s 2022 Annual Report on Form 10-K as filed with the SEC on March 1, 2023 (the “2022 Form 10-K”). The accompanying Unaudited Condensed Consolidated Balance Sheet and related disclosures as of December 31, 2022 have been derived from the Company’s audited financial statements. The Company’s financial condition as of June 30, 2023, and operating results for the three and six months ended June 30, 2023, are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the year ending December 31, 2023.

LIQUIDITY AND SIGNIFICANT ACCOU

LIQUIDITY AND SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
LIQUIDITY AND SIGNIFICANT ACCOUNTING POLICIES	LIQUIDITY AND SIGNIFICANT ACCOUNTING POLICIES Liquidity As of June 30, 2023, the Company’s current liabilities exceeded its current assets by $64.2 million, and the Company recorded net income of $4.3 million for the three months ended June 30, 2023. As of June 30, 2023, the Company had available cash, cash equivalents and restricted cash of $124.0 million and short-term investments of $17.1 million. As of June 30, 2023, the Company’s current liabilities included $259.1 million of deferred revenue whereby the historical costs of fulfilling the Company's commitments to provide services to its clients was approximately 37% of the related deferred revenue for the three months ended June 30, 2023. On July 20, 2021, the Company entered into a five-year term loan of $90 million (the “Credit Facility”). Annual minimum principal payments over the five-year term for the Credit Facility are 5%, 5%, 7.5%, 7.5% and 10%, respectively, with the remaining balance due at the end of the term. See Note 5 for further information regarding the Company's Credit Facility. Additionally, the Company is obligated to make operating and financing lease payments that are due within the next 12 months in the aggregate amount of $5.9 million. During the second quarter of 2023, the U.S. economy continued to experience rising interest rates and inflationary pressures due in part to the recent bank failures within the U.S. banking sector, global supply chain issues, a rise in energy prices and the continuing effects of fiscal and monetary policies adopted by governments in response to the global outbreak of the coronavirus (“COVID-19”). As of the issuance date of these financial statements, the Company’s ability to operate continues not to be significantly adversely impacted by the related changes in the macroeconomic environment, and the Company believes that current cash, cash equivalents, restricted cash, and future cash flow from operating activities will be sufficient to meet the Company’s anticipated cash needs, including Credit Facility repayments, working capital needs, capital expenditures and other contractual obligations for at least 12 months from the issuance date of these financial statements. Use of Estimates The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires the Company to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s accounting estimates include, but are not necessarily limited to, valuation of accounts receivable, valuation assumptions for stock options and leases, deferred income taxes and the related valuation allowances, and the evaluation and measurement of contingencies. To the extent there are material differences between the Company’s estimates and actual results, the Company’s future consolidated results of operations may be affected. Recent Accounting Pronouncements Recently Adopted Standards. The following accounting standards were adopted during fiscal year 2023: In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, and amended in December 2022 with ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. ASU 2020-04 provides guidance to alleviate the burden in accounting for reference rate reform by allowing certain expedients and exceptions in applying U.S. GAAP to contracts, hedging relationships and other transactions impacted by reference rate reform. The provisions apply only to those transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued due to reference rate reform. Adoption of the provisions of ASU 2020-04 are optional and are effective from March 12, 2020 through December 31, 2024, as amended by ASU 2022-06. During the three months ended March 31, 2023, the Company adopted the optional relief guidance provided under ASU 2020-04 after modifying its interest rate swap agreement in connection with the amendment of the Credit Facility to implement certain changes in the reference rate from LIBOR to the Secured Overnight Financing Rate (“SOFR”). The application of this expedient preserves the presentation of the derivative consistent with past presentation and did not have a material impact on our Unaudited Condensed Consolidated Financial Statements.

DEFERRED CONTRACT COSTS AND DEF

DEFERRED CONTRACT COSTS AND DEFERRED REVENUE	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
DEFERRED CONTRACT COSTS AND DEFERRED REVENUE	DEFERRED CONTRACT COSTS AND DEFERRED REVENUE Activity for deferred contract costs consisted of the following (in thousands): Three Months Ended Six Months Ended June 30, 2023 2022 2023 2022 Deferred contract costs, current and noncurrent, as of the beginning of period $ 39,299 $ 38,821 $ 40,726 $ 36,509 Capitalized commissions during the period 5,555 5,278 8,717 11,803 Amortized deferred contract costs during the period (4,748) (4,390) (9,337) (8,603) Deferred contract costs, current and noncurrent, as of the end of period $ 40,106 $ 39,709 $ 40,106 $ 39,709 Deferred revenue activity consisted of the following (in thousands): Three Months Ended Six Months Ended June 30, 2023 2022 2023 2022 Deferred revenue, current and noncurrent, as of the beginning of period $ 287,381 $ 300,029 $ 299,921 $ 300,268 Billings, net 104,364 101,558 197,336 199,229 Revenue recognized (106,421) (101,200) (211,933) (199,110) Deferred revenue, current and noncurrent, as of the end of period $ 285,324 $ 300,387 $ 285,324 $ 300,387 The Company’s remaining performance obligations represent all future non-cancellable revenue under contract that has not yet been recognized as revenue and includes deferred revenue and unbilled amounts. As of June 30, 2023, remaining performance obligations amounted to $565.1 million, of which $285.3 million was billed and recorded as deferred revenue. As of June 30, 2022, remaining performance obligations amounted to $550.6 million, of which $300.4 million was billed and recorded as deferred revenue.

OTHER FINANCIAL INFORMATION

OTHER FINANCIAL INFORMATION	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
OTHER FINANCIAL INFORMATION	OTHER FINANCIAL INFORMATION Other Accrued Liabilities Other accrued liabilities consisted of the following (in thousands): June 30, December 31, 2023 2022 Accrued sales and other taxes $ 5,739 $ 6,878 Accrued professional fees 3,338 9,184 Accrued reorganization costs — 2,526 Current maturities of capital lease obligations 346 333 Income taxes payable 1,157 2,229 Accrued litigation settlement costs 6,982 6,979 Other accrued expenses 4,107 4,547 Total other accrued liabilities $ 21,669 $ 32,676

DEBT

DEBT	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
DEBT	DEBT Debt is presented net of debt discounts and issuance costs in the Company's balance sheets and consisted of the following (in thousands): June 30, December 31, 2023 2022 Credit Facility $ 73,025 $ 74,792 Less current maturities 5,912 4,789 Long-term debt, net of current maturities $ 67,113 $ 70,003 On February 22, 2023, the Company amended its Credit Facility. The amendment implemented, among other things, certain changes in the reference rate from LIBOR to the SOFR. Effective February 28, 2023, the Company has a choice of interest rates between (a) Adjusted Term SOFR and (b) Base Rate (as defined in the Credit Facility), in each case plus an applicable margin. The applicable margin remains the same as the existing Credit Agreement and is based on the Company’s Consolidated Leverage Ratio (as defined in the Credit Agreement) and whether the Company elects Adjusted Term SOFR (ranging from 1.75 to 2.50%) or Base Rate (ranging from 0.75 to 1.50%). In addition, the amendment adjusted the definition of Consolidated EBITDA to provide an addback solely for the fourth fiscal quarter of 2022, and any period including such quarter, that costs and legal fees and expenses incurred by the Company in connection with its ongoing litigation with Oracle up to $10.0 million can be added back and included in the applicable calculation of Consolidated EBITDA. Based on voluntary prepayments made to date under the Credit Facility, the Company currently has available $40 million in incremental borrowings available for future use, subject to the terms of the Credit Facility. On May 31, 2022, the Company amended the Credit Facility to increase the aggregate value of the shares of Common Stock that can be repurchased by the Company to $50 million during the term of the Credit Facility. On June 30, 2023 and March 31, 2023, the Company made both of its required principal payments of $1.1 million, respectively. On June 30, 2022 and March 31, 2022, the Company also made its required two principal payments of $1.1 million, respectively. On May 31, 2022, the Company prepaid $5.0 million of indebtedness outstanding under its Credit Facility with no prepayment penalty. Effective July 20, 2021, the Company received $89.3 million of net proceeds pursuant to the Credit Facility. The borrowings under the Credit Facility were incurred with an original discount of 0.375%. As part of the transaction, the Company incurred issuance costs of $4.2 million, which were capitalized and are being amortized over the term of the Credit Facility. The Credit Facility originally bore interest at LIBOR, plus a margin ranging from 1.75% to 2.50% through February 28, 2023. Subsequently, the Credit Facility was amended to bear interest at SOFR as noted above. For the three months ended June 30, 2023 and 2022, the average interest rate on the Credit Facility was 6.85% and 2.76%, respectively. For the six months ended June 30, 2023 and 2022, the average interest rate on the Credit Facility was 6.58% and 2.61%, respectively. On May 18, 2022, the Company entered into an interest rate swap agreement with a notional value of $40 million, with a fixed payer LIBOR rate of 2.9935% and an initial floating LIBOR rate of 0.93557%. The floating rate is reset at each month end and had an embedded floor rate of 0.0%. The term of the interest rate swap agreement coincides with that of the Credit Facility. See Note 11 for further information regarding the fair value accounting for the interest rate swap agreement. Effective February 28, 2023, the interest rate swap agreement was amended in connection with the amendment of the Credit Facility to implement certain changes in the reference rate from LIBOR to SOFR. The fair value of the Credit Facility was $76.6 million (Level 2 inputs) as of June 30, 2023 compared to the carrying value of $75.6 million as of June 30, 2023. The fair value of the Credit Facility was $78.8 million (Level 2 inputs) as of December 31, 2022 compared to the carrying value of $77.8 million as of December 31, 2022. The Credit Facility contains certain financial covenants, including a minimum fixed charge coverage ratio greater than 1.25, a total leverage ratio less than 3.75, and a minimum liquidity balance of at least $20 million in U.S. cash. Annual minimum principal payments over the five-year term for the Credit Facility are 5%, 5%, 7.5%, 7.5%, and 10%, respectively, with the remaining balance due at the end of the term. Pursuant to a Guaranty and Security Agreement, dated July 2, 2021 (the “Guaranty and Security Agreement”), among the Credit Parties and Capital One, National Association, as agent, the obligations under the Credit Facility are guaranteed by certain of the Company’s subsidiaries (the Company and the guarantors, collectively, the “Credit Parties”) and are secured, subject to customary permitted liens and exceptions, by a lien on substantially all assets of the Credit Parties. The components of interest expense are presented below (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Credit Facility: Interest expense $ 1,126 $ 735 $ 2,204 $ 1,277 Accretion expense related to discount and issuance costs 243 243 483 483 Interest on finance leases 18 21 39 47 $ 1,387 $ 999 $ 2,726 $ 1,807

COMMON STOCK OFFERING, RESTRICT

COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS	COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS Common Stock Retired On May 28, 2022, the Board of Directors authorized an increase to the Company’s previously announced Common Stock repurchase program to increase the value of the shares that could be acquired by the Company from up to $15.0 million over two years to up to $50.0 million over the next four years, subject to compliance with the Company’s Credit Facility, provided that all other applicable conditions and legal requirements are satisfied. On February 27, 2022, the Board of Directors approved the adoption of a stock repurchase program to acquire up to $15.0 million of the Company’s Common Stock both on the open market and in privately negotiated transactions, including through Rule 10b5-1 plans, through March 4, 2024, subject to compliance with the Company's Credit Facility, which was amended effective January 14, 2022 to increase the aggregate value of the shares of Common Stock that could be acquired by the Company to no greater than $15.0 million during the term of the Credit Facility, provided that all other applicable conditions and legal requirements are satisfied. During the three and six months ended June 30, 2023, the Company acquired 0.2 million shares of its Common Stock on the open market at a cost of $1.0 million. For the three months ended June 30, 2022, the Company acquired 0.1 million shares of its Common Stock on the open market at a cost of $0.5 million. For the six months ended June 30, 2022, the Company acquired an aggregate 0.7 million shares of Common Stock on the open market at a total cost of $3.7 million. Upon completion of all repurchase transactions, the associated shares of Common Stock were retired. Stock Plans The Company’s stock plans consist of the 2007 Stock Plan (the “2007 Plan”) and the 2013 Equity Incentive Plan, as amended and restated in July 2017 (the “2013 Plan”). The 2007 Plan and the 2013 Plan are collectively referred to as the “Stock Plans”. On February 23, 2023, pursuant to the “evergreen” provisions of the 2013 Plan, the Board of Directors authorized an increase of approximately 3.5 million shares available for grant under the 2013 Plan. For additional information about the Stock Plans, please refer to Note 8 to the Company’s Consolidated Financial Statements for the year ended December 31, 2022, included in Part II, Item 8 of the 2022 Form 10-K. The information presented below provides an update for activity under the Stock Plans for the three and six months ended June 30, 2023. On March 31, 2023, the Company’s Board of Directors, approved the Company’s 2023 Long-Term Incentive Plan (the “2023 LTI Plan”), consisting of awards of performance units (“PSUs”), restricted stock units (“RSUs”) and stock options to purchase shares of the Company’s Common Stock under the terms of the Company’s 2013 Equity Incentive Plan (the “2013 Equity Plan”), as amended, effective as of April 3, 2023. Performance Units The PSUs awarded under the 2023 LTI Plan (the “Target PSUs”) will be measured over a performance period beginning on January 1, 2023 and ending on December 31, 2023 (the “Performance Period”), but will remain subject to a continued service-based vesting requirement. Half of the PSUs awarded will be eligible to vest based on the Company’s achievement against a target adjusted EBITDA goal for fiscal year 2023, and the remaining half of the PSUs awarded will be eligible to vest based on the Company’s achievement against a target total revenue goal for fiscal year 2023. The ultimate number of PSUs that may vest (as calculated, the “Earned PSUs”) range from zero to 200% of the Target PSUs. Under the terms of the 2023 LTI Plan, the Earned PSUs will vest in equal annual installments on the first, second and third anniversaries of the Date of Grant, generally subject to the awardee continuing to be a Service Provider through the applicable vesting date. The Company granted 0.6 million PSUs on April 3, 2023 at a grant price of $3.93. The Company recognized compensation expense of $0.3 million for the three months and six months ended June 30, 2023. Restricted Stock Units For the six months ended June 30, 2023, the Board of Directors granted RSUs under the 2013 Plan to employees and to non-employee members of the Board of Directors for an aggregate of approximately 1.3 million shares of Common Stock. RSU grants vest over periods generally ranging from 12 to 36 months from the respective grant dates and the awards are subject to forfeiture upon termination of employment or service on the Board of Directors, as applicable. Based on the weighted average fair market value of the Common Stock on the date of grant of $4.27 per share, the aggregate fair value for the shares underlying the RSUs amounted to $5.4 million as of the grant date that will be recognized as compensation cost over the vesting period. For the three months ended June 30, 2023 and 2022, the Company recognized compensation expense related to RSUs of approximately $2.6 million and $2.2 million, respectively. For the six months ended June 30, 2023 and 2022, the Company recognized expense of $4.0 million and $4.8 million, respectively. As of June 30, 2023, the unrecognized expense of $8.4 million net of forfeitures is expected to be charged to expense on a straight-line basis as the RSUs vest over a weighted-average period of approximately 1.7 years. Stock Options For the six months ended June 30, 2023, the Board of Directors granted stock options for the purchase of an aggregate of approximately 1.8 million shares of Common Stock at exercise prices that were equal to the fair market value of the Common Stock on the date of grant. Options granted to employees generally vest as to one-third of the shares subject to the award on each anniversary of the designated vesting commencement date, which may precede the grant date of such award, and expire ten years after the grant date. The following table sets forth a summary of stock option activity under the Stock Plans for the six months ended June 30, 2023 (shares in thousands): Shares Price (1) Term (2) Outstanding, December 31, 2022 6,994 $ 6.17 5.5 Granted 1,818 4.27 Forfeited (232) 6.03 Expired (148) 7.08 Exercised (57) 1.38 Outstanding, June 30, 2023 (3)(4) 8,375 5.78 6.0 Vested, June 30, 2023 (3) 5,050 6.19 4.0 (1) Represents the weighted average exercise price. (2) Represents the weighted average remaining contractual term until the stock options expire, in years. (3) As of June 30, 2023, the aggregate intrinsic value of all stock options outstanding was $1.4 million. As of June 30, 2023, the aggregate intrinsic value of vested stock options was $0.3 million. (4) The number of outstanding stock options that are not expected to ultimately vest due to forfeiture amounted to 0.5 million shares as of June 30, 2023. The following table presents activity affecting the total number of shares available for grant under the Stock Plans for the six months ended June 30, 2023 (in thousands): Available, December 31, 2022 7,543 Newly authorized by Board of Directors 3,541 Stock options granted (1,818) RSUs and PSUs granted (1,871) Expired options under Stock Plans 148 Forfeited options under Stock Plans 232 Forfeited RSUs under Stock Plans 151 Retired shares of Common Stock 248 Issuance of Common Stock (75) Available, June 30, 2023 8,099 The aggregate fair value of approximately 1.8 million stock options granted for the six months ended June 30, 2023 amounted to $4.3 million, or $2.36 per stock option as of the grant date utilizing the Black-Scholes-Merton (“BSM”) method. The fair valued derived under the BSM method will result in the recognition of compensation cost over the vesting period of the stock options. For the six months ended June 30, 2023, the fair value of each stock option grant under the Stock Plans was estimated on the date of grant using the BSM option-pricing model, with the following weighted-average assumptions: Expected life (in years) 6.0 Volatility 55% Dividend yield 0% Risk-free interest rate 3.73% Fair value per share of Common Stock on date of grant $4.27 As of June 30, 2023 and December 31, 2022, total unrecognized compensation costs related to unvested stock options, net of estimated forfeitures, was $6.0 million and $4.1 million, respectively. As of June 30, 2023, the unrecognized costs are expected to be charged to expense on a straight-line basis over a weighted-average vesting period of approximately 2.2 years. Stock-Based Compensation Expense Stock-based compensation expense attributable to RSUs and stock options is classified as follows (in thousands): Three Months Ended Six Months Ended June 30, 2023 2022 2023 2022 Cost of revenue $ 507 $ 573 $ 920 $ 1,081 Sales and marketing 791 853 1,249 1,680 General and administrative 2,650 1,733 3,756 3,449 Total $ 3,948 $ 3,159 $ 5,925 $ 6,210 Warrants

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES On August 16, 2022, the Inflation Reduction Act of 2022 (the “IRA”) was signed into law. The IRA includes a 15% corporate alternative minimum tax for companies that report over $1 billion in U.S. profits to shareholders and a 1% excise tax on stock buy backs. The Company does not expect the IRA to have a material tax impact. For the three months ended June 30, 2023 and 2022, the Company’s effective tax rate was 53.5% and 96.5%, respectively. For the six months ended June 30, 2023 and 2022, the Company’s effective tax rate was 48.0% and 62.2%, respectively. The Company’s income tax expense was primarily attributable to earnings in the United States and foreign jurisdictions subject to income taxes and foreign withholding taxes. The Company did not have any material changes to its conclusions regarding valuation allowances for deferred income tax assets or uncertain tax positions for the three and six months ended June 30, 2023 and 2022.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Retirement Plan The Company has defined contribution plans for both its U.S. and foreign employees. For certain of these plans, employees may contribute up to the statutory maximum, which is set by law each year. The plans also provide for employer contributions. For the three months ended June 30, 2023 and 2022, the Company’s matching contributions to these plans totaled $0.8 million and $1.1 million, respectively. For the six months ended June 30, 2023 and 2022, the Company’s matching contributions to these plans totaled $1.7 million and $2.0 million, respectively. Rimini I Litigation In January 2010, certain subsidiaries of Oracle Corporation (together with its subsidiaries individually and collectively, “Oracle”) filed a lawsuit, Oracle USA, Inc. et al. v. Rimini Street, Inc. et al. (United States District Court for the District of Nevada) (the “District Court”) (“Rimini I”), against the Company and its Chief Executive Officer and President, Seth Ravin, alleging that certain of the Company’s processes (Process 1.0) violated Oracle’s license agreements with its customers and that the Company committed acts of copyright infringement and violated other federal and state laws. The litigation involved the Company’s business processes and the manner in which the Company provided services to its clients. After completion of a jury trial in 2015 and subsequent appeals, the final outcome of Rimini I was that Mr. Ravin was found not liable for any claims and the Company was found liable for only one claim: “innocent infringement,” a jury finding that the Company did not know and had no reason to know that its former support processes were infringing. The jury also found that the infringement did not cause Oracle to suffer lost profits. The Company was ordered to pay a judgment of $124.4 million in 2016, which the Company promptly paid and then pursued appeals. With interest, attorneys’ fees and costs, the total judgment paid by the Company to Oracle after the completion of all appeals was approximately $89.9 million. A portion of such judgment was paid by the Company’s insurance carriers. Rimini I Injunction Proceedings Since November 2018, the Company has been subject to a permanent injunction (the “Rimini I Injunction”) prohibiting it from using certain support processes that had been found in Rimini I to “innocently” infringe certain Oracle copyrights. The Rimini I Injunction does not prohibit the Company’s provision of support services for any Oracle product lines, but rather defines the manner in which the Company can provide support services for certain Oracle product lines. In July 2020, Oracle filed a motion to show cause contending that the Company was in violation of the Rimini I Injunction, and the Company opposed this motion, disputing Oracle’s claims. In January 2022, the District Court issued its findings and order following an evidentiary hearing held in September 2021 regarding whether the Company (i) violated the Rimini I Injunction for certain accused conduct and (ii) should be held in contempt in those instances where the District Court found a violation of the Rimini I Injunction, and what sanctions, if any, are appropriate. In the order, the District Court ruled in favor of the Company with respect to five of the items. With respect to the other five items, the District Court found the Company violated the Rimini I Injunction, awarded sanctions to Oracle of $0.6 million and ordered that certain computer files be quarantined from use and notice and proof of such quarantining be provided to Oracle. The District Court also ruled that Oracle may recover its reasonable attorneys’ fees and costs. The Company reserved all rights, including appellate rights, with respect to the District Court rulings and findings. In February 2022, Rimini filed a notice of appeal in the District Court, commencing an appeal of the District Court’s January 2022 decision to the Ninth Circuit Court of Appeals (“Court of Appeals”). Shortly thereafter, the District Court stayed the briefing on Oracle’s bill of attorneys’ fees and costs until Rimini’s appeal is resolved. Briefing on Rimini’s appeal has been completed. Oral argument on the appeal was held in San Francisco in February 2023, and the Court of Appeals has not yet issued a decision on the appeal. At this time, the Company believes that it is in substantial compliance with the Rimini I Injunction and has complied with the order regarding the quarantining of certain computer files. As of June 30, 2023 and December 31, 2022, the Company had accrued $6.9 million, respectively, as an estimate related to reasonable attorneys’ fees and costs. During the six months ended June 30, 2022, the Company paid $0.6 million to Oracle for the sanctions award. Regarding the Company’s estimate for reasonable attorneys’ fees and costs, significant judgment is required to determine the amount of loss related to this matter as the outcome is inherently unpredictable and subject to uncertainties. Rimini II Litigation In October 2014, the Company filed a separate lawsuit, Rimini Street Inc. v. Oracle Int’l Corp. , in the District Court against Oracle seeking a declaratory judgment that the Company’s revised “Process 2.0” support practices, in use since at least July 2014, did not infringe certain Oracle copyrights (“Rimini II”). The Company’s operative complaint asserted declaratory judgment, tort, and statutory claims, including a request for injunctive relief against Oracle for unfair competition in violation of the California Unfair Competition Law. Oracle’s operative counterclaim asserted declaratory judgment and copyright infringement claims, including violations of the Digital Millennium Copyright Act (“DMCA”), and Lanham Act, breach of contract, and business tort violations with respect to PeopleSoft and other Oracle-branded products, including J.D. Edwards, Siebel, Oracle Database and Oracle E-Business Suite (“EBS”). During a status conference with the District Court in mid-October 2022, attorneys for Oracle confirmed that Oracle would withdraw all of its monetary damages claims against the Company and the Company’s CEO and President, Mr. Ravin in Rimini II and proceed with a bench trial instead of a jury trial for its claims for equitable relief. The District Court entered an order on October 24, 2022, dismissing with prejudice Oracle’s claims in Rimini II “for monetary relief of any kind under any legal theory [,] including but not limited to claims for damages, restitution, unjust enrichment, and engorgement [ . . . ].” In addition, Oracle’s claims for breach of contract, inducing breach of contract and an accounting, were dismissed with prejudice, meaning that the claims (including for monetary damages) have been dismissed on their merits and that the judgement rendered is final. When claims have been dismissed with prejudice, a litigant is prohibited from bringing a future court action on the same claims. Prior to the date of the District Court’s order dismissing with prejudice all of Oracle’s claims for monetary relief, no damages of any kind were awarded by the District Court in Rimini II. The parties each reserved the right to seek attorneys’ fees and/or costs to the extent permissible by law. The Rimini II bench trial began in Las Vegas on November 29, 2022 and concluded on December 15, 2022. The parties submitted their proposed findings of fact and conclusions of law to the District Court in February 2023. Subsequent Event On July 24, 2023, the District Court issued its findings of fact and conclusions of law in Rimini II, accompanied by a permanent injunction against the Company (the “Rimini II Injunction”). The District Court found infringement as to Oracle’s PeopleSoft and Oracle Database products but did not find infringement as to Oracle’s EBS, Siebel and J.D. Edwards products, further ordering that the Company was entitled to a declaration of non-infringement for Oracle’s EBS product. The District Court also found that Oracle could not obtain injunctive relief for the Oracle Database product since it had not requested such relief in the proposed injunction that it submitted to the District Court. The District Court also found in favor of Oracle on its DMCA and Lanham Act claims, and on indirect and vicarious copyright infringement claims against the Company’s CEO and President, Mr. Ravin. The District Court denied the Company’s California Unfair Competition Law claim and other declaratory judgment claims. The Rimini II Injunction is primarily directed at Oracle’s PeopleSoft software product. The Rimini II Injunction currently limits, but does not fully prohibit, the support services the Company can provide its clients using Oracle’s PeopleSoft software product. The percentage of revenue derived from support services the Company provides solely for Oracle’s PeopleSoft software product was approximately 8% of the Company’s total revenue during the fiscal second quarter of 2023. The Rimini II Injunction requires the Company to immediately and permanently delete certain PeopleSoft software environments, files and updates identified in the Injunction, as well as to delete and immediately and permanently discontinue use of certain Company-created automated tools. The Rimini II Injunction also specifies that the Company shall not remove, alter or omit any Oracle copyright notices or other Oracle copyright management information from any file that contains an Oracle copyright notice. Finally, the Rimini II Injunction prohibits the Company from publicly making statements or statements substantially similar to those the District Court found to be “false and misleading,” which are listed in the Rimini II Injunction. In connection therewith, no later than August 23, 2023, the Company is required to issue a corrective press release (in a form prescribed by the District Court) regarding these “false and misleading statements” and maintain a copy of this press release on its public website for at least five years. The Company is also required to certify in writing no later than September 22, 2023, the manner and form in which it has complied with the Rimini II Injunction. On July 25, 2023, the Company filed a notice of appeal in the District Court, commencing an appeal of the District Court’s July 24, 2023 decision and the Rimini II Injunction. On July 28, 2023, the Company filed an emergency motion with the District Court to stay enforcement of the Rimini II Injunction pending its appeal. On July 30, 2023, the District Court issued an order setting an expedited briefing schedule for Rimini’s emergency stay motion, with Oracle’s response due by August 7, 2023 and the Company’s reply due by August 11, 2023. While the Company plans to continue to vigorously pursue a stay of the Rimini II Injunction and its appeal, it is unable to predict the timing or outcome of these matters. No assurance is or can be given that the Company will succeed in its efforts to stay the Rimini II Injunction or prevail in all or part of its appeal. There were no monetary damages included in the District Court’s ruling and findings in Rimini II. To date, Oracle has not filed a motion with the District Court seeking attorneys’ fees and costs. Therefore, we do not believe that Oracle’s attorneys’ fees and costs are estimatable or probable at this time. The Company maintains that Oracle should not be permitted to recover any of its attorneys’ fees and/or costs, but the Company also reserves its right to seek recovery of its attorneys’ fees and/or costs. A decision about whether to award any attorneys’ fees and/or costs to either party, and if so, the amounts, will be made by the District Court. The change to how certain support services are delivered by the Company to clients receiving support for Oracle’s PeopleSoft products will likely result in additional future period costs to comply with the Rimini II Injunction. However, these costs are not currently estimatable and are not required to be recorded as of June 30, 2023. Accordingly, the Company has made no associated accrual as of June 30, 2023. Any adverse outcome could have a material impact on the Company’s financial position, results of operations and cash flows. The Company reserves all rights, including appellate rights, with respect to the District Court’s rulings and findings in Rimini II and the Rimini II Injunction, including any award of attorneys’ fees and costs to Oracle. Other Litigation From time to time, the Company may be a party to litigation and subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that the final outcome of these ordinary course matters will not have a material adverse effect on its business. Regardless of the outcome, litigation can have an adverse impact on the Company because of judgment, defense and settlement costs, diversion of management resources and other factors. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimatable under ASC 450, Contingencies . Legal fees are expensed as incurred. Liquidated Damages The Company enters into agreements with clients that contain provisions related to liquidated damages that would be triggered in the event that the Company is no longer able to provide services to these clients. The maximum cash payments related to these liquidated damages is approximately $13.7 million and $8.1 million as of June 30, 2023 and December 31, 2022, respectively. To date, the Company has not incurred any costs as a result of such provisions and has not accrued any liabilities related to such provisions in these Unaudited Condensed Consolidated Financial Statements.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS An affiliate of Adams Street Partners and its affiliates (collectively referred to as “ASP”) is a member of the Company’s Board of Directors. As of June 30, 2023, ASP owned approximately 26.5% of the Company’s issued and outstanding shares of Common Stock.

EARNINGS PER SHARE

EARNINGS PER SHARE	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE The Company computes earnings per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings per share of Common Stock is computed by dividing net income attributable to common stockholders by the weighted average number of shares of basic Common Stock outstanding. Diluted earnings per share of Common Stock is calculated by adjusting the basic earnings per share of Common Stock for the effects of potential dilutive Common Stock shares outstanding such as stock options, restricted stock units and warrants. For the three months ended June 30, 2023 and 2022, basic and diluted net earnings per share of Common Stock were computed by dividing the net income attributable to common stockholders by the weighted average number of common shares outstanding during the respective periods. The following tables set forth the computation of basic and diluted net income attributable to common stockholders (in thousands, except per share amounts): Three Months Ended Six Months Ended June 30, 2023 2022 2023 2022 Income attributable to common stockholders: Net income $ 4,268 $ 110 $ 9,907 $ 3,197 Three Months Ended Six Months Ended June 30, 2023 2022 2023 2022 Weighted average number of shares of Common Stock outstanding: Basic 88,903 87,225 88,797 87,175 Warrants — 181 — — Stock options 17 659 33 588 RSUs 354 1,274 421 1,177 Diluted 89,274 89,339 89,251 88,940 Net income per share attributable to common stockholders: Basic $ 0.05 $ — $ 0.11 $ 0.04 Diluted $ 0.05 $ — $ 0.11 $ 0.04 The following potential Common Stock equivalents were excluded from the computation of diluted net income per share for the respective periods ending on these dates, since the impact of inclusion was anti-dilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 RSUs 1,574 691 1,013 507 Stock options 8,149 4,046 7,558 4,020 Warrants 3,440 14,688 3,440 18,128 Total 13,163 19,425 12,011 22,655

FINANCIAL INSTRUMENTS AND SIGNI

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS	6 Months Ended
	Jun. 30, 2023
Investments, All Other Investments [Abstract]
FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS	FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Fair Value Measurements Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. Additional information on fair value measurements is included in Note 13 to the Company’s Consolidated Financial Statements for the year ended December 31, 2022, included in Part II, Item 8 of the 2022 Form 10-K. The Company’s policy is to recognize asset or liability transfers among Level 1, Level 2 and Level 3 as of the actual date of the events or change in circumstances that caused the transfer. Investments During September 2022, the Company invested $20 million of its cash and cash equivalents into U.S. Federal agency bonds, U.S. government bonds, U.S. treasury notes and other securities. We consider all highly liquid interest-earning investments with a maturity of three months or less at the date of purchase to be cash equivalents. The fair values of these investments approximate their carrying values. In general, investments with original maturities of greater than three months and remaining maturities of less than one year are classified as short-term investments. Debt investments are classified as available-for-sale and gains and losses are recorded using the specific identification method. Changes in fair value are recorded in the operating statement. Fair value is calculated based on publicly available market information. Listed below are the cash equivalent and investment balances as of June 30, 2023 (in thousands): Fair Value Level Cost Basis Unrealized Gains (Losses) Recorded Basis Cash Equivalents Short-term Investments Long-term Investments Federal Agency Bonds Level 2 $ 15,213 $ 139 $ 15,352 $ 404 $ 12,919 $ 2,029 US Treasury notes Level 2 5,180 29 5,209 998 4,211 — $ 20,393 $ 168 $ 20,561 $ 1,402 $ 17,130 $ 2,029 Derivatives On May 18, 2022, the Company entered into an interest rate swap agreement for a notional value of $40.0 million. The derivative was recognized in the accompanying Unaudited Condensed Consolidated Balance Sheets at its estimated fair value as of June 30, 2023. The Company uses derivatives to manage the risk associated with changes in interest rates. The Company does not enter into derivatives for speculative purposes. To estimate fair value for the Company's interest rate swap agreement as of June 30, 2023, the Company utilized a present value of future cash flows, leveraging a model-derived valuation that uses Level 2 observable inputs such as interest rate yield curves. The Company estimated the fair value of the interest rate swap agreement to be $1.6 million as of June 30, 2023. Changes in the fair value of the derivatives that qualify as cash flow hedges are recorded in Accumulated other comprehensive loss in the accompanying Unaudited Condensed Consolidated Balance Sheets until earnings are affected by the variability of the cash flows. The Company received interest swap payments of $0.2 million and $0.4 million during the three and six months ended June 30, 2023, respectively, which were recorded as a reduction to interest expense. The Company incurred interest payments of $0.1 million during the three and six months ended June 30, 2022, which were recorded as interest expense. The amounts recorded for the interest rate swap agreement are described below (in thousands): Derivative Instrument Balance Sheet Classification June 30, 2023 December 31, 2022 Interest rate swap Deposits and other $ 1,616 $ 1,402 Accumulated other comprehensive loss 1,270 1,107 Three Months Ended June 30, Six Months Ended June 30, Derivative Instrument Income Statement Classification 2023 2022 2023 2022 Interest rate swap Interest expense (benefit) $ (208) $ 142 $ (365) $ 142 Significant Concentrations The Company attributes revenues to geographic regions based on the location of its clients’ contracting entities. The following table shows revenues by geographic region (in thousands): Three Months Ended Six Months Ended June 30, 2023 2022 2023 2022 United States of America $ 53,973 $ 53,909 $ 107,406 $ 106,194 International 52,448 47,291 104,527 92,916 Total $ 106,421 $ 101,200 $ 211,933 $ 199,110 No clients represented more than 10% of revenue for both the three and six months ended June 30, 2023 and 2022. As of June 30, 2023 and December 31, 2022, no clients accounted for more than 10% of total net accounts receivable. The Company tracks its assets by physical location. As of June 30, 2023 and December 31, 2022, the net carrying value of the Company’s property and equipment located outside of the United States amounted to approximately $1.8 million and $1.8 million respectively. As of June 30, 2023, the Company had operating lease right-of-use assets of $3.6 million, $2.7 million and $0.9 million in the United States, India and the rest of the world, respectively. As of December 31, 2022, the Company had operating lease right-of-use assets of $2.6 million, $3.4 million and $1.2 million in the United States, India and the rest of the world, respectively. Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, and accounts receivable. The Company maintains its cash, cash equivalents and restricted cash at high-quality financial institutions, primarily in the United States. Deposits, including those held in foreign branches of global banks, may exceed the amount of insurance provided on such deposits. As of June 30, 2023 and December 31, 2022, the Company had cash, cash equivalents and restricted cash with a single financial institution for an aggregate of $47.4 million and $44.9 million, respectively. In addition, as of June 30, 2023 the Company had cash and cash equivalents with two other single financial institutions of $26.6 million. As of June 30, 2023 and December 31, 2022, the Company had restricted cash of $0.4 million. The Company has never experienced any losses related to these balances. Generally, credit risk with respect to accounts receivable is diversified due to the number of entities comprising the Company’s client base and their dispersion across different geographies and industries. The Company performs ongoing credit evaluations on certain clients and generally does not require collateral on accounts receivable. The Company maintains reserves for potential bad debts and historically such losses are generally not significant.

LEASES

LEASES	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
LEASES	LEASES Effective at the start of fiscal 2020, the Company adopted the provisions and expanded disclosure requirements described in Accounting Standards Codification (ASC) Topic 842, Lease s. The Company adopted the standard using the prospective method. The Company has operating leases for real estate and equipment with an option to renew the leases for up to one month to five years. Some of the leases include the option to terminate the leases upon 30-days’ notice with a penalty. The Company’s leases have various remaining lease terms ranging from July 2023 to December 2028. The Company’s lease agreements may include renewal or termination options for varying periods that are generally at the Company's discretion. The Company’s lease terms only include those periods related to renewal options the Company believes are reasonably certain to exercise. The Company generally does not include these renewal options as it is not reasonably certain to renew at the lease commencement date. This determination is based on consideration of certain economic, strategic and other factors that the Company evaluates at lease commencement date and reevaluates throughout the lease term. Some leases also include options to terminate the leases and the Company only includes those periods beyond the termination date if it is reasonably certain not to exercise the termination option. The Company uses a discount rate to calculate the right of use (“ROU”) asset and lease liability. When the implicit rate is known or provided in the lease documents, the Company is required to use this rate. In cases in which the implicit rate is not known, the Company uses an estimated incremental borrowing rate. Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as payments for insurance and tax payments. The variable portion of lease payments is not included in the Company’s ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred and are included in lease expenses recorded in selling and administrative expenses on the Consolidated Statements of Operations and Comprehensive Income. The Company has lease agreements with both lease and non-lease components that are treated as a single lease component for all underlying asset classes. Accordingly, all expenses associated with a lease contract are accounted for as lease expenses. The Company has elected to apply the short-term lease exception for all underlying asset classes. That is, leases with a term of 12 months or less are not recognized on the balance sheet, but rather expensed on a straight-line basis over the lease term. The Company’s leases do not include significant restrictions or covenants, and residual value guarantees are generally not included within its operating leases. As of June 30, 2023, the Company did not have any material additional operating leases that have not yet commenced. The components of lease expense and supplemental balance sheet information were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating lease expense related to ROU assets and liabilities $ 1,090 $ 1,377 $ 2,237 $ 2,781 Other lease expense 125 211 173 403 Total lease expense $ 1,215 $ 1,588 $ 2,410 $ 3,184 Other information related to leases was as follows (in thousands): Supplemental Balance Sheet Information June 30, 2023 December 31, 2022 Operating lease right-of-use assets, noncurrent $ 7,138 $ 7,142 June 30, 2023 December 31, 2022 Operating lease liabilities, current $ 4,219 $ 4,223 Operating lease liabilities, noncurrent 8,532 9,094 Total operating lease liabilities $ 12,751 $ 13,317 Weighted Average Remaining Lease Term Years Operating leases 3.16 Weighted Average Discount Rate Operating leases 9.9 % Maturities of operating lease liabilities as of June 30, 2023 were as follows (in thousands): Year Ending June 30, 2024 $ 5,198 2025 4,513 2026 2,795 2027 1,795 2028 363 Thereafter 185 Total future undiscounted lease payments 14,849 Less imputed interest (2,098) Total $ 12,751

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net income	$ 4,268	$ 110	$ 9,907	$ 3,197

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

LIQUIDITY AND SIGNIFICANT ACC_2

LIQUIDITY AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Nature of Business	Nature of Business
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The Unaudited Condensed Consolidated Financial Statements, which include the accounts of the Company and its wholly-owned subsidiaries, are prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”). All significant intercompany balances and transactions have been eliminated. The accompanying Unaudited Condensed Consolidated Financial Statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, certain information and footnote disclosures required by U.S. GAAP for complete financial statements have been condensed or omitted in accordance with such rules and regulations. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Unaudited Condensed Consolidated Financial Statements have been included. These Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company’s Audited Consolidated Financial Statements for the year ended December 31, 2022, included in the Company’s 2022 Annual Report on Form 10-K as filed with the SEC on March 1, 2023 (the “2022 Form 10-K”). The accompanying Unaudited Condensed Consolidated Balance Sheet and related disclosures as of December 31, 2022 have been derived from the Company’s audited financial statements. The Company’s financial condition as of June 30, 2023, and operating results for the three and six months ended June 30, 2023, are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the year ending December 31, 2023.
Use of Estimates	Use of Estimates The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires the Company to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Standards. The following accounting standards were adopted during fiscal year 2023: In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, and amended in December 2022 with ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. ASU 2020-04 provides guidance to alleviate the burden in accounting for reference rate reform by allowing certain expedients and exceptions in applying U.S. GAAP to contracts, hedging relationships and other transactions impacted by reference rate reform. The provisions apply only to those transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued due to reference rate reform. Adoption of the provisions of ASU 2020-04 are optional and are effective from March 12, 2020 through December 31, 2024, as amended by ASU 2022-06. During the three months ended March 31, 2023, the Company adopted the optional relief guidance provided under ASU 2020-04 after modifying its interest rate swap agreement in connection with the amendment of the Credit Facility to implement certain changes in the reference rate from LIBOR to the Secured Overnight Financing Rate (“SOFR”). The application of this expedient preserves the presentation of the derivative consistent with past presentation and did not have a material impact on our Unaudited Condensed Consolidated Financial Statements.
Earnings Per Share	The Company computes earnings per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings per share of Common Stock is computed by dividing net income attributable to common stockholders by the weighted average number of shares of basic Common Stock outstanding. Diluted earnings per share of Common Stock is calculated by adjusting the basic earnings per share of Common Stock for the effects of potential dilutive Common Stock shares outstanding such as stock options, restricted stock units and warrants.

DEFERRED CONTRACT COSTS AND D_2

DEFERRED CONTRACT COSTS AND DEFERRED REVENUE (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Deferred Revenue	Activity for deferred contract costs consisted of the following (in thousands): Three Months Ended Six Months Ended June 30, 2023 2022 2023 2022 Deferred contract costs, current and noncurrent, as of the beginning of period $ 39,299 $ 38,821 $ 40,726 $ 36,509 Capitalized commissions during the period 5,555 5,278 8,717 11,803 Amortized deferred contract costs during the period (4,748) (4,390) (9,337) (8,603) Deferred contract costs, current and noncurrent, as of the end of period $ 40,106 $ 39,709 $ 40,106 $ 39,709 Deferred revenue activity consisted of the following (in thousands): Three Months Ended Six Months Ended June 30, 2023 2022 2023 2022 Deferred revenue, current and noncurrent, as of the beginning of period $ 287,381 $ 300,029 $ 299,921 $ 300,268 Billings, net 104,364 101,558 197,336 199,229 Revenue recognized (106,421) (101,200) (211,933) (199,110) Deferred revenue, current and noncurrent, as of the end of period $ 285,324 $ 300,387 $ 285,324 $ 300,387

OTHER FINANCIAL INFORMATION (Ta

OTHER FINANCIAL INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Other Accrued Liabilities	Other accrued liabilities consisted of the following (in thousands): June 30, December 31, 2023 2022 Accrued sales and other taxes $ 5,739 $ 6,878 Accrued professional fees 3,338 9,184 Accrued reorganization costs — 2,526 Current maturities of capital lease obligations 346 333 Income taxes payable 1,157 2,229 Accrued litigation settlement costs 6,982 6,979 Other accrued expenses 4,107 4,547 Total other accrued liabilities $ 21,669 $ 32,676

DEBT (Tables)

DEBT (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Carrying Value of Debt	Debt is presented net of debt discounts and issuance costs in the Company's balance sheets and consisted of the following (in thousands): June 30, December 31, 2023 2022 Credit Facility $ 73,025 $ 74,792 Less current maturities 5,912 4,789 Long-term debt, net of current maturities $ 67,113 $ 70,003
Schedule of Interest Expense	The components of interest expense are presented below (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Credit Facility: Interest expense $ 1,126 $ 735 $ 2,204 $ 1,277 Accretion expense related to discount and issuance costs 243 243 483 483 Interest on finance leases 18 21 39 47 $ 1,387 $ 999 $ 2,726 $ 1,807

COMMON STOCK OFFERING, RESTRI_2

COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	The following table sets forth a summary of stock option activity under the Stock Plans for the six months ended June 30, 2023 (shares in thousands): Shares Price (1) Term (2) Outstanding, December 31, 2022 6,994 $ 6.17 5.5 Granted 1,818 4.27 Forfeited (232) 6.03 Expired (148) 7.08 Exercised (57) 1.38 Outstanding, June 30, 2023 (3)(4) 8,375 5.78 6.0 Vested, June 30, 2023 (3) 5,050 6.19 4.0 (1) Represents the weighted average exercise price. (2) Represents the weighted average remaining contractual term until the stock options expire, in years. (3) As of June 30, 2023, the aggregate intrinsic value of all stock options outstanding was $1.4 million. As of June 30, 2023, the aggregate intrinsic value of vested stock options was $0.3 million. (4) The number of outstanding stock options that are not expected to ultimately vest due to forfeiture amounted to 0.5 million shares as of June 30, 2023.
Schedule of Stockholders Equity	The following table presents activity affecting the total number of shares available for grant under the Stock Plans for the six months ended June 30, 2023 (in thousands): Available, December 31, 2022 7,543 Newly authorized by Board of Directors 3,541 Stock options granted (1,818) RSUs and PSUs granted (1,871) Expired options under Stock Plans 148 Forfeited options under Stock Plans 232 Forfeited RSUs under Stock Plans 151 Retired shares of Common Stock 248 Issuance of Common Stock (75) Available, June 30, 2023 8,099
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	For the six months ended June 30, 2023, the fair value of each stock option grant under the Stock Plans was estimated on the date of grant using the BSM option-pricing model, with the following weighted-average assumptions: Expected life (in years) 6.0 Volatility 55% Dividend yield 0% Risk-free interest rate 3.73% Fair value per share of Common Stock on date of grant $4.27
Schedule of Stock-based Compensation Expense	Stock-based compensation expense attributable to RSUs and stock options is classified as follows (in thousands): Three Months Ended Six Months Ended June 30, 2023 2022 2023 2022 Cost of revenue $ 507 $ 573 $ 920 $ 1,081 Sales and marketing 791 853 1,249 1,680 General and administrative 2,650 1,733 3,756 3,449 Total $ 3,948 $ 3,159 $ 5,925 $ 6,210

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following tables set forth the computation of basic and diluted net income attributable to common stockholders (in thousands, except per share amounts): Three Months Ended Six Months Ended June 30, 2023 2022 2023 2022 Income attributable to common stockholders: Net income $ 4,268 $ 110 $ 9,907 $ 3,197 Three Months Ended Six Months Ended June 30, 2023 2022 2023 2022 Weighted average number of shares of Common Stock outstanding: Basic 88,903 87,225 88,797 87,175 Warrants — 181 — — Stock options 17 659 33 588 RSUs 354 1,274 421 1,177 Diluted 89,274 89,339 89,251 88,940 Net income per share attributable to common stockholders: Basic $ 0.05 $ — $ 0.11 $ 0.04 Diluted $ 0.05 $ — $ 0.11 $ 0.04
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following potential Common Stock equivalents were excluded from the computation of diluted net income per share for the respective periods ending on these dates, since the impact of inclusion was anti-dilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 RSUs 1,574 691 1,013 507 Stock options 8,149 4,046 7,558 4,020 Warrants 3,440 14,688 3,440 18,128 Total 13,163 19,425 12,011 22,655

FINANCIAL INSTRUMENTS AND SIG_2

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables)	6 Months Ended
	Jun. 30, 2023
Investments, All Other Investments [Abstract]
Schedule of Cash Equivalent And Short-Term Investment Balances	Listed below are the cash equivalent and investment balances as of June 30, 2023 (in thousands): Fair Value Level Cost Basis Unrealized Gains (Losses) Recorded Basis Cash Equivalents Short-term Investments Long-term Investments Federal Agency Bonds Level 2 $ 15,213 $ 139 $ 15,352 $ 404 $ 12,919 $ 2,029 US Treasury notes Level 2 5,180 29 5,209 998 4,211 — $ 20,393 $ 168 $ 20,561 $ 1,402 $ 17,130 $ 2,029
Schedule of Amounts Recorded For Interest Rate Swap Agreements	The amounts recorded for the interest rate swap agreement are described below (in thousands): Derivative Instrument Balance Sheet Classification June 30, 2023 December 31, 2022 Interest rate swap Deposits and other $ 1,616 $ 1,402 Accumulated other comprehensive loss 1,270 1,107 Three Months Ended June 30, Six Months Ended June 30, Derivative Instrument Income Statement Classification 2023 2022 2023 2022 Interest rate swap Interest expense (benefit) $ (208) $ 142 $ (365) $ 142
Schedule of Revenues by Geographic Regions	The following table shows revenues by geographic region (in thousands): Three Months Ended Six Months Ended June 30, 2023 2022 2023 2022 United States of America $ 53,973 $ 53,909 $ 107,406 $ 106,194 International 52,448 47,291 104,527 92,916 Total $ 106,421 $ 101,200 $ 211,933 $ 199,110

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Schedule of Components of Lease Expense	The components of lease expense and supplemental balance sheet information were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating lease expense related to ROU assets and liabilities $ 1,090 $ 1,377 $ 2,237 $ 2,781 Other lease expense 125 211 173 403 Total lease expense $ 1,215 $ 1,588 $ 2,410 $ 3,184 Other information related to leases was as follows (in thousands): Supplemental Balance Sheet Information June 30, 2023 December 31, 2022 Operating lease right-of-use assets, noncurrent $ 7,138 $ 7,142 June 30, 2023 December 31, 2022 Operating lease liabilities, current $ 4,219 $ 4,223 Operating lease liabilities, noncurrent 8,532 9,094 Total operating lease liabilities $ 12,751 $ 13,317 Weighted Average Remaining Lease Term Years Operating leases 3.16 Weighted Average Discount Rate Operating leases 9.9 %
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities as of June 30, 2023 were as follows (in thousands): Year Ending June 30, 2024 $ 5,198 2025 4,513 2026 2,795 2027 1,795 2028 363 Thereafter 185 Total future undiscounted lease payments 14,849 Less imputed interest (2,098) Total $ 12,751

LIQUIDITY AND SIGNIFICANT ACC_3

LIQUIDITY AND SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)		3 Months Ended		6 Months Ended
	Jul. 20, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Working capital deficit				$ 64,200,000
Net income		$ 4,268,000	$ 110,000	9,907,000	$ 3,197,000
Cash, cash equivalents, restricted cash and restricted cash equivalents		123,970,000	$ 160,636,000	123,970,000	$ 160,636,000	$ 109,434,000	$ 119,990,000
Short-term investments		17,130,000		17,130,000		$ 20,115,000
Deferred revenue, current		$ 259,100,000		259,100,000
Cost of goods and services sold (as percentage of revenue)		37%
Consulting agreement, term (in years)	5 years
Face amount of debt	$ 90,000,000
Annual minimum principal payments year one	5%
Annual minimum principal payments year two	5%
Annual minimum principal payments year three	7.50%
Annual minimum principal payments year four	7.50%
Annual minimum principal payments year five	10%
Operating and capital lease payments due within next twelve months		$ 5,900,000		$ 5,900,000

DEFERRED CONTRACT COSTS AND D_3

DEFERRED CONTRACT COSTS AND DEFERRED REVENUE - Schedule of Deferred Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Capitalized Contract Cost, Net [Abstract]
Deferred contract costs, current and noncurrent, as of the beginning of period	$ 39,299	$ 38,821	$ 40,726	$ 36,509
Capitalized commissions during the period	5,555	5,278	8,717	11,803
Amortized deferred contract costs during the period	(4,748)	(4,390)	(9,337)	(8,603)
Deferred contract costs, current and noncurrent, as of the end of period	40,106	39,709	40,106	39,709
Change in Contract with Customer, Liability [Abstract]
Deferred revenue, current and noncurrent, as of the beginning of period	287,381	300,029	299,921	300,268
Billings, net	104,364	101,558	197,336	199,229
Revenue recognized	(106,421)	(101,200)	(211,933)	(199,110)
Deferred revenue, current and noncurrent, as of the end of period	$ 285,324	$ 300,387	$ 285,324	$ 300,387

DEFERRED CONTRACT COSTS AND D_4

DEFERRED CONTRACT COSTS AND DEFERRED REVENUE- Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Revenue Recognition and Deferred Revenue [Abstract]
Performance obligation	$ 565,100			$ 550,600
Contract with customer, liability	285,324	$ 287,381	$ 299,921	$ 300,387	$ 300,029	$ 300,268
Deferred revenue, current	$ 259,102		$ 265,840

OTHER FINANCIAL INFORMATION - O

OTHER FINANCIAL INFORMATION - Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued sales and other taxes	$ 5,739	$ 6,878
Accrued professional fees	3,338	9,184
Accrued reorganization costs	0	2,526
Current maturities of capital lease obligations	346	333
Income taxes payable	1,157	2,229
Accrued litigation settlement costs	6,982	6,979
Other accrued expenses	4,107	4,547
Total other accrued liabilities	$ 21,669	$ 32,676
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total other accrued liabilities	Total other accrued liabilities

DEBT - Schedule of Carrying Val

DEBT - Schedule of Carrying Value of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Less current maturities	$ 5,912	$ 4,789
Long-term debt, net of current maturities	67,113	70,003
Line of Credit
Debt Instrument [Line Items]
Credit Facility	73,025	74,792
Less current maturities	5,912	4,789
Long-term debt, net of current maturities	$ 67,113	$ 70,003

DEBT - Narrative (Details)

DEBT - Narrative (Details)						3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Feb. 22, 2023	May 31, 2022 USD ($)	Jul. 20, 2021 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($) payment	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($) payment	Dec. 31, 2022 USD ($)	May 27, 2022 USD ($)	May 18, 2022 USD ($)	Mar. 31, 2022 USD ($) payment	Feb. 27, 2022 USD ($)	Jan. 14, 2022 USD ($)
Debt Instrument [Line Items]
Value of shares authorized to be repurchased				$ 50,000,000							$ 15,000,000			$ 15,000,000	$ 15,000,000
Consulting agreement, term (in years)					5 years
Annual minimum principal payments year one					5%
Annual minimum principal payments year two					5%
Annual minimum principal payments year three					7.50%
Annual minimum principal payments year four					7.50%
Annual minimum principal payments year five					10%
Interest rate swap agreement
Debt Instrument [Line Items]
Notional amount												$ 40,000,000
Fixed payer LIBOR Rate (percent)												2.9935%
Initial floating LIBOR rate (percent)												0.93557%
Embedded floor (percent)												0%
Proceeds from interest received						$ 200,000		$ 400,000
Line of Credit
Debt Instrument [Line Items]
Minimum fixed charge ratio					1.25
Debt instrument, leverage ratio					3.75
Consulting agreement, term (in years)					5 years
Annual minimum principal payments year one					5%
Annual minimum principal payments year two					5%
Annual minimum principal payments year three					7.50%
Annual minimum principal payments year four					7.50%
Annual minimum principal payments year five					10%
Line of Credit | 2023 Amended Credit Facility
Debt Instrument [Line Items]
Litigation liability limit						10,000,000
Incremental borrowings available	$ 40,000,000					$ 40,000,000		$ 40,000,000
Periodic payment amount of principal	1,100,000	$ 1,100,000
Number of required principal payments | payment							2		2				2
Principal payment							$ 1,100,000		$ 1,100,000				$ 1,100,000
Prepaid indebtedness				5,000,000
Prepayment penalty				$ 0
Line of Credit | July 2021 Credit Facility
Debt Instrument [Line Items]
Proceeds from credit facility					$ 89,300,000
Issuance costs discount (percent)					0.375%
Incurred issuance costs					$ 4,200,000
Line of credit facility, interest rate						6.85%	2.76%	6.58%	2.61%
Fair value of the carrying amount	75,600,000					$ 75,600,000		$ 75,600,000		$ 77,800,000
Line of Credit | Level 2 | July 2021 Credit Facility
Debt Instrument [Line Items]
Fair value of the credit facility	$ 76,600,000					$ 76,600,000		$ 76,600,000		$ 78,800,000
Line of Credit | Minimum
Debt Instrument [Line Items]
Financial covenants, minimum liquidity					$ 20,000,000
Line of Credit | Adjusted Term SOFR | Minimum | 2023 Amended Credit Facility
Debt Instrument [Line Items]
Debt instrument, interest rate spread (percent)			1.75%
Line of Credit | Adjusted Term SOFR | Maximum | 2023 Amended Credit Facility
Debt Instrument [Line Items]
Debt instrument, interest rate spread (percent)			2.50%
Line of Credit | Base Rate | Minimum | 2023 Amended Credit Facility
Debt Instrument [Line Items]
Debt instrument, interest rate spread (percent)			0.75%
Line of Credit | Base Rate | Maximum | 2023 Amended Credit Facility
Debt Instrument [Line Items]
Debt instrument, interest rate spread (percent)			1.50%
Line of Credit | LIBOR | Minimum | July 2021 Credit Facility
Debt Instrument [Line Items]
Debt instrument, interest rate spread (percent)					1.75%
Line of Credit | LIBOR | Maximum | July 2021 Credit Facility
Debt Instrument [Line Items]
Debt instrument, interest rate spread (percent)					2.50%

DEBT - Schedule of Interest Exp

DEBT - Schedule of Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Debt Instrument [Line Items]
Interest on finance leases	$ 18	$ 21	$ 39	$ 47
Interest expense	1,387	999	2,726	1,807
Line of Credit
Debt Instrument [Line Items]
Interest expense	1,126	735	2,204	1,277
Accretion expense related to discount and issuance costs	$ 243	$ 243	$ 483	$ 483

COMMON STOCK OFFERING, RESTRI_3

COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands					3 Months Ended		6 Months Ended
	Apr. 03, 2023	May 31, 2022	May 27, 2022	Feb. 22, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Feb. 27, 2022	Jan. 14, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of shares authorized to be repurchased		$ 50,000	$ 15,000							$ 15,000	$ 15,000
Stock repurchase program, period		4 years	2 years
Stock reacquired and retired (shares)					200	100	248	700
Stock reacquired and retired					$ 1,000	$ 500	$ 1,000	$ 3,700
Stock Plans
Stock available for grant newly authorized by Board of Directors (shares)				3,500			3,541
Performance Units
Performance units (shares)							1,871
Stock-based compensation expense					3,948	3,159	$ 5,925	6,210
Restricted Stock Units
Restricted stock units granted in period (shares)							1,871
Stock-based compensation expense					$ 3,948	3,159	$ 5,925	6,210
Stock Options
Stock options granted in period (shares)							1,818
Warrants
Warrants outstanding (shares)					3,400		3,400
Exercise price of warrants (in USD per share)					$ 5.64		$ 5.64
Stock options
Restricted Stock Units
Period for recognition of compensation costs not yet recognized related to nonvested awards							2 years 2 months 12 days
Stock Options
Stock options granted in period (shares)							1,800
Fair value of stock options granted							$ 4,300
Weighted-average grant date fair value per share of options granted in period (usd per share)							$ 2.36
Unrecognized compensation costs					$ 6,000		$ 6,000		$ 4,100
Period for recognition of compensation costs not yet recognized related to nonvested awards							2 years 2 months 12 days
Performance Units PSUs
Performance Units
Award vesting rights (percentage)							33.33%
Performance units (shares)	600
Performance units grant of price (USD per share)	$ 3.93
Stock-based compensation expense					300		$ 300
Restricted Stock Units
Restricted stock units granted in period (shares)	600
Share price of common stock on date of grant of RSUs (USD per share)	$ 3.93
Stock-based compensation expense					300		$ 300
Stock Options
Award vesting rights (percentage)							33.33%
2013 Plan | RSUs
Performance Units
Performance units (shares)							1,300
Performance units grant of price (USD per share)							$ 4.27
Stock-based compensation expense					2,600	2,200	$ 4,000	4,800
Restricted Stock Units
Restricted stock units granted in period (shares)							1,300
Share price of common stock on date of grant of RSUs (USD per share)							$ 4.27
Aggregate fair value of shares underlying RSU's							$ 5,400
Stock-based compensation expense					2,600	$ 2,200	4,000	$ 4,800
Compensation costs not yet recognized of nonvested awards					$ 8,400		$ 8,400
Period for recognition of compensation costs not yet recognized related to nonvested awards							1 year 8 months 12 days
Stock Options
Period for recognition of compensation costs not yet recognized related to nonvested awards							1 year 8 months 12 days
2013 Plan | Stock options
Performance Units
Award vesting rights (percentage)							33.33%
Stock Options
Award vesting rights (percentage)							33.33%
Stock Plans | Stock options
Stock Options
Term of vested options (years)							10 years
Vesting eligibility target - adjusted EBITDA goal | Performance Units PSUs
Performance Units
Vesting eligibility (percent)					50%		50%
Vesting eligibility target - total revenue goal | Performance Units PSUs
Performance Units
Vesting eligibility (percent)					50%		50%
Minimum | Performance Units PSUs
Performance Units
Ultimate number of PSU's that may vest as a percentage of the target PSUs (percent)					0%		0%
Minimum | 2013 Plan | RSUs
Restricted Stock Units
Award vesting period							12 months
Maximum | Performance Units PSUs
Performance Units
Ultimate number of PSU's that may vest as a percentage of the target PSUs (percent)					200%		200%
Maximum | 2013 Plan | RSUs
Restricted Stock Units
Award vesting period							36 months

COMMON STOCK OFFERING, RESTRI_4

COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS - Schedule of Stock Option Activity (Details) $ / shares in Units, shares in Thousands, $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2022 $ / shares shares
Shares
Granted (shares)	1,818
Forfeited (shares)	(232)
Expired (shares)	(148)
Vested at end of period (shares)	500
Stock Options Plans
Shares
Outstanding at beginning of period (shares)	6,994
Granted (shares)	1,818
Forfeited (shares)	(232)
Expired (shares)	(148)
Exercised (shares)	(57)
Outstanding at end of period (shares)	8,375	6,994
Vested at end of period (shares)	5,050
Price
Outstanding at beginning of period (USD per share) | $ / shares	$ 6.17
Granted (USD per share) | $ / shares	4.27
Forfeited (USD per share) | $ / shares	6.03
Expired (USD per share) | $ / shares	7.08
Exercised (USD per share) | $ / shares	1.38
Outstanding at end of period (USD per share) | $ / shares	5.78	$ 6.17
Vested (USD per share) | $ / shares	$ 6.19
Term
Term of outstanding options	6 years	5 years 6 months
Term of vested options (years)	4 years
Aggregate intrinsic value of stock options outstanding | $	$ 1.4
Aggregate intrinsic value of vested stock options | $	$ 0.3

COMMON STOCK OFFERING, RESTRI_5

COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS - Schedule of Stockholders Equity (Details) - shares shares in Thousands		3 Months Ended		6 Months Ended
	Feb. 22, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Shares Available for Grant [Roll Forward]
Available at beginning of period (shares)				7,543
Newly authorized by Board of Directors (shares)	3,500			3,541
Stock options granted (shares)				(1,818)
RSUs granted (shares)				(1,871)
Expired options under Stock Plans (shares)				148
Forfeited options under Stock Plans (shares)				232
Forfeited RSUs under Stock Plans (shares)				151
Retired shares of Common Stock (shares)		200	100	248	700
Issuance of Common Stock (shares)				(75)
Available at end of period (shares)		8,099		8,099

COMMON STOCK OFFERING, RESTRI_6

COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	6 Months Ended
	Jun. 30, 2023 $ / shares
Share-Based Payment Arrangement [Abstract]
Expected life (in years)	6 years
Volatility (as a percent)	55%
Dividend yield (as a percent)	0%
Risk-free interest rate (as a percent)	3.73%
Fair value per common share on date of grant (USD per share)	$ 4.27

COMMON STOCK OFFERING, RESTRI_7

COMMON STOCK OFFERING, RESTRICTED STOCK UNITS, STOCK OPTIONS AND WARRANTS - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 3,948	$ 3,159	$ 5,925	$ 6,210
Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	507	573	920	1,081
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	791	853	1,249	1,680
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 2,650	$ 1,733	$ 3,756	$ 3,449

INCOME TAXES (Details)

INCOME TAXES (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Federal statutory income tax rate (as a percent)	53.50%	96.50%	48%	62.20%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) $ in Millions		1 Months Ended	3 Months Ended			6 Months Ended		24 Months Ended
	Jan. 12, 2022 USD ($) claim	Aug. 23, 2023	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2017 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2016 claim	Dec. 31, 2022 USD ($)
Loss Contingencies [Line Items]
Employer contribution			$ 0.8	$ 1.1		$ 1.7	$ 2
Current carrying value of guarantor obligations			$ 13.7			13.7			$ 8.1
Software | Revenue Benchmark | Customer Concentration Risk
Loss Contingencies [Line Items]
Concentration risk percent (more than)			8%
Oracle Litigation
Loss Contingencies [Line Items]
Number of claim found liable | claim								1
Damages awarded					$ 124.4
Payments for judgement ordered after fees and costs					$ 89.9
Rimini I Injunction Proceedings
Loss Contingencies [Line Items]
Damages awarded	$ 0.6
Number of claims ruled in favor of defendant | claim	5
Number of claims ruled in favor of plaintiff | claim	5
Accrued expense			$ 6.9			$ 6.9			$ 6.9
Amount awarded to other party							$ 0.6
Rimini II Injunction | Forecast
Loss Contingencies [Line Items]
Litigation, to maintain the public website		5 years

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)	6 Months Ended
	Jun. 30, 2023
Adams Street Partners | Related Party | Rimini Street, Inc.
Related Party Transaction [Line Items]
Ownership of common stock outstanding (as a percent)	26.50%

EARNINGS PER SHARE - Schedule o

EARNINGS PER SHARE - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net income	$ 4,268	$ 110	$ 9,907	$ 3,197
Weighted average number of shares outstanding, basic (shares)	88,903	87,225	88,797	87,175
Weighted average number of shares outstanding, diluted (shares)	89,274	89,339	89,251	88,940
Basic (in dollars per share)	$ 0.05	$ 0	$ 0.11	$ 0.04
Diluted (in dollars per share)	$ 0.05	$ 0	$ 0.11	$ 0.04
Warrants
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Dilutive effect of securities (shares)	0	181	0	0
Stock options
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Dilutive effect of securities (shares)	17	659	33	588
RSUs
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Dilutive effect of securities (shares)	354	1,274	421	1,177

EARNINGS PER SHARE - Schedule_2

EARNINGS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings (in shares)	13,163	19,425	12,011	22,655
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings (in shares)	1,574	691	1,013	507
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings (in shares)	8,149	4,046	7,558	4,020
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings (in shares)	3,440	14,688	3,440	18,128

FINANCIAL INSTRUMENTS AND SIG_3

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Sep. 30, 2022	May 18, 2022	Dec. 31, 2021
Concentration Risk [Line Items]
Investment of cash, and cash equivalents						$ 20,000
Cash paid for interest			$ 2,256	$ 1,277
Operating lease right-of-use assets	$ 7,138		7,138		$ 7,142
Cash, cash equivalents, restricted cash and restricted cash equivalents	123,970	$ 160,636	123,970	160,636	109,434			$ 119,990
Cash and cash equivalents	123,543		123,543		109,008
Interest rate swap agreement
Concentration Risk [Line Items]
Notional amount							$ 40,000
Interest rate swap	1,600		1,600
Proceeds from interest received	200		400
Cash paid for interest		$ 100		$ 100
Single Financial Institution
Concentration Risk [Line Items]
Cash, cash equivalents, restricted cash and restricted cash equivalents	47,400		47,400		44,900
Cash and cash equivalents	26,600		26,600
Current restricted cash	400		400		400
Non-US
Concentration Risk [Line Items]
Property and equipment, net	1,800		1,800		1,800
UNITED STATES
Concentration Risk [Line Items]
Operating lease right-of-use assets	3,600		3,600		2,600
INDIA
Concentration Risk [Line Items]
Operating lease right-of-use assets	2,700		2,700		3,400
Rest of the world
Concentration Risk [Line Items]
Operating lease right-of-use assets	$ 900		$ 900		$ 1,200

FINANCIAL INSTRUMENTS AND SIG_4

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Schedule of Cash Equivalent And Short-Term Investment Balances (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Debt Securities, Available-for-Sale [Line Items]
Cost Basis	$ 20,393
Unrealized Gains (Losses)	168
Recorded Basis	20,561
Cash Equivalents
Debt Securities, Available-for-Sale [Line Items]
Recorded Basis	1,402
Short-term Investments
Debt Securities, Available-for-Sale [Line Items]
Recorded Basis	17,130
Long-term Investments
Debt Securities, Available-for-Sale [Line Items]
Recorded Basis	2,029
Federal Agency Bonds | Level 2
Debt Securities, Available-for-Sale [Line Items]
Cost Basis	15,213
Unrealized Gains (Losses)	139
Recorded Basis	15,352
Federal Agency Bonds | Cash Equivalents | Level 2
Debt Securities, Available-for-Sale [Line Items]
Recorded Basis	404
Federal Agency Bonds | Short-term Investments | Level 2
Debt Securities, Available-for-Sale [Line Items]
Recorded Basis	12,919
Federal Agency Bonds | Long-term Investments | Level 2
Debt Securities, Available-for-Sale [Line Items]
Recorded Basis	2,029
US Treasury notes | Level 2
Debt Securities, Available-for-Sale [Line Items]
Cost Basis	5,180
Unrealized Gains (Losses)	29
Recorded Basis	5,209
US Treasury notes | Cash Equivalents | Level 2
Debt Securities, Available-for-Sale [Line Items]
Recorded Basis	998
US Treasury notes | Short-term Investments | Level 2
Debt Securities, Available-for-Sale [Line Items]
Recorded Basis	4,211
US Treasury notes | Long-term Investments | Level 2
Debt Securities, Available-for-Sale [Line Items]
Recorded Basis	$ 0

FINANCIAL INSTRUMENTS AND SIG_5

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Schedule of Amounts Recorded For Interest Rate Swap Agreement (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Derivatives, Fair Value [Line Items]
Interest expense (benefit)	$ 1,387	$ 999	$ 2,726	$ 1,807
Deposits and other
Derivatives, Fair Value [Line Items]
Interest rate swap	1,616		1,616		$ 1,402
Accumulated other comprehensive loss
Derivatives, Fair Value [Line Items]
Interest rate swap	1,270		1,270		$ 1,107
Interest rate swap agreement
Derivatives, Fair Value [Line Items]
Interest rate swap	1,600		1,600
Interest expense (benefit)	$ (208)	$ 142	$ (365)	$ 142

FINANCIAL INSTRUMENTS AND SIG_6

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Schedule of Revenues by Geographic Regions (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 106,421	$ 101,200	$ 211,933	$ 199,110
United States of America
Disaggregation of Revenue [Line Items]
Revenue	53,973	53,909	107,406	106,194
International
Disaggregation of Revenue [Line Items]
Revenue	$ 52,448	$ 47,291	$ 104,527	$ 92,916

LEASES - Narrative (Details)

LEASES - Narrative (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($) day	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) day	Jun. 30, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Days notice required to terminate (days) | day	30		30
Operating lease payments | $	$ 1.7	$ 1.4	$ 2.8	$ 2.8
Minimum
Lessee, Lease, Description [Line Items]
Operating lease renewal term (years)	1 month		1 month
Maximum
Lessee, Lease, Description [Line Items]
Operating lease renewal term (years)	5 years		5 years

LEASES - Schedule of Components

LEASES - Schedule of Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Leases [Abstract]
Operating lease expense related to ROU assets and liabilities	$ 1,090	$ 1,377	$ 2,237	$ 2,781
Other lease expense	125	211	173	403
Total lease expense	$ 1,215	$ 1,588	$ 2,410	$ 3,184

LEASES - Schedule of Supplement

LEASES - Schedule of Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Leases [Abstract]
Operating lease right-of-use assets, noncurrent	$ 7,138	$ 7,142
Operating lease liabilities, current	4,219	4,223
Operating lease liabilities, noncurrent	8,532	9,094
Total operating lease liabilities	$ 12,751	$ 13,317
Weighted average remaining lease term, operating leases (years)	3 years 1 month 28 days
Weighted average discount rate, operating leases (as a percent)	9.90%

LEASES - Schedule of Maturities

LEASES - Schedule of Maturities of Lease Liability (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Leases [Abstract]
2024	$ 5,198
2025	4,513
2026	2,795
2027	1,795
2028	363
Thereafter	185
Total future undiscounted lease payments	14,849
Less imputed interest	(2,098)
Total	$ 12,751	$ 13,317